Evobrutinib, a highly selective BTK inhibitor for the treatment of relapsing multiple sclerosis, showed long-term safety and success in reducing annualized relapse rates.
The director of the Kansas City Multiple Sclerosis Center at College Park Neurology, discusses goals of therapy in patients with relapsing multiple sclerosis, especially for the subset of patients in which steroids are not an option or are ineffective.

SAP Partner Banner